Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira®
April 8 2022: Reykjavik, Iceland — Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that is has executed a U.S. settlement agreement with AbbVie (NYSE: ABBV) that grants Alvotech non-exclusive rights to market AVT02 (100mg/mL), its high-concentration, citrate-free biosimilar candidate for Humira® (adalimumab) in the United States. The settlement grants Alvotech a license entry date in the United States of July 1, 2023.
Access to content from the Arctic Knowledge Archives is available to subscribers only.
Please sign in to continue, or choose your subscription for unlimited access.
All memberships are considered donations to support this non-profit effort. Institutions and groups should contact us directly for pricing.
Already a subscriber? Log in
Membership
You may select only one level from this group.
Individual Annual
$150.00
Year
Individual Monthly
$15.00
Month
